CTI BioPharma Corp. (CTIC)
Stock Price:
$3.50 USD
0.16 (4.79%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $3.59 +0.09 (2.57%) Oct 23, 7:53 PM
Key Info
| Market Cap |
356.81M |
| Revenue (ttm) |
2.29M |
| Net Income (ttm) |
-44.42M |
| Shares Out |
73.72M |
| EPS (ttm) |
-0.71 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$3.50 |
| Previous Close |
$3.34 |
| Change ($) |
0.16 |
| Change (%) |
4.79% |
| Day's Open |
3.40 |
| Day's Range |
3.40 - 3.60 |
| Day's Volume |
2,006,842 |
| 52-Week Range |
0.62 - 3.68 |
More Stats
| Market Cap |
356.81M |
| Enterprise Value |
293.56M |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
73.72M |
| Float |
66.39M |
| EPS (basic) |
-0.70 |
| EPS (diluted) |
-0.71 |
| FCF / Share |
-0.50 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
311,860 |
| Short Ratio |
0.06 |
| Short % of Float |
0.47% |
| Beta |
0.98 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
155.88 |
| PB Ratio |
4.33 |
| Revenue |
2.29M |
| Operating Income |
-41.11M |
| Net Income |
-44.42M |
| Free Cash Flow |
-37.09M |
| Net Cash |
63.25M |
| Net Cash / Share |
0.62 |
| Gross Margin |
146.13% |
| Operating Margin |
-1,796.11% |
| Profit Margin |
-1,940.60% |
| FCF Margin |
-1,620.36% |
| ROA |
-32.35% |
| ROE |
-96.72% |
| ROIC |
-1,451.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.00*
(71.43% upside)
Low
4.00
Current: $3.50
High
8.00
Target: 6.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 3.35 | 26.29 | 25.15 | 57.41 | 16.12 | 60.08 | 34.68 | - | - | 0.32 |
| Revenue Growth | -87.28% | 4.55% | -56.2% | 256.2% | -73.17% | 73.24% | - | - | - | - |
| Gross Profit | 3.35 | 26.29 | 24.78 | 56.03 | 14.18 | 59.18 | 34.54 | - | - | 0.32 |
| Operating Income | -40.71 | -32.90 | -39.52 | -49.16 | -117 | -86.23 | -41.53 | -101 | -62.19 | -78.40 |
| Net Income | -40.02 | -29.32 | -40.67 | -52.01 | -119 | -93.37 | -42.74 | -101 | -62.36 | -82.64 |
| Shares Outstanding | 57.97 | 56.07 | 36.45 | 27.95 | 18.84 | 14.85 | 11.42 | 5.81 | 3.43 | 2.28 |
| Earnings Per Share | -0.69 | -0.52 | -1.24 | -1.86 | -6.51 | -6.46 | -4.30 | -19.80 | -35.30 | -64.70 |
| Operating Cash Flow | -27.82 | -39.82 | -39.30 | -76.68 | -95.20 | -39.55 | -35.83 | -62.78 | -60.46 | -63.13 |
| Capital Expenditures | - | -0.03 | -0.05 | -0.14 | -0.08 | -0.33 | -1.53 | -2.94 | -2.67 | -1.93 |
| Free Cash Flow | -27.82 | -39.86 | -39.35 | -76.82 | -95.28 | -39.88 | -37.36 | -65.71 | -63.13 | -65.05 |
| Cash & Equivalents | 33.67 | 67.04 | 43.22 | 44.00 | 128 | 70.93 | 71.64 | 50.44 | 47.05 | 22.65 |
| Total Debt | 9.27 | 14.08 | 14.02 | 19.26 | 56.50 | 17.38 | 13.31 | - | 3.96 | 28.23 |
| Net Cash / Debt | 24.40 | 52.96 | 29.20 | 24.74 | 71.69 | 53.56 | 58.33 | 50.44 | 43.10 | -5.58 |
| Assets | 46.28 | 89.83 | 54.89 | 63.84 | 144 | 92.29 | 93.72 | 73.71 | 62.24 | 53.59 |
| Liabilities | 28.35 | 36.89 | 38.80 | 56.09 | 96.78 | 52.36 | 37.50 | 27.31 | 20.77 | 45.28 |
| Book Value | 23.69 | 58.69 | 21.81 | 13.32 | 52.03 | 41.76 | 45.17 | 34.55 | 28.72 | -4.75 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CTI BioPharma Corp. |
| Country |
United States |
| Employees |
25 |
| CEO |
Adam R. Craig |
Stock Information
| Ticker Symbol |
CTIC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CTIC |
| IPO Date |
March 21, 1997 |
Description
CTI BioPharma, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.